Pyodermas are among bacterial skin diseases often resisting antibiotic therapy. We therefore examined how the dogs with deep pyoderma (n = 29) respond to therapeutic effect of antibiotic cephalexins (Ceporex ® , 30 mg·kg -1 p.o., once a day for 9 -11 weeks) combined with immunomodulators (Baypamune ® , once a week i.m. pro toto). The dogs with the fi rst occurrence of pyoderma (n = 11) were treated by antibiotics alone, whereas the dogs with recurrent pyoderma (n = 18) were treated by either antibiotics alone (n = 8) or antibiotics combined with Baypamune ® (n = 10). Of 11 dogs with the fi rst occurrence of disease, 8 (73%) were successfully cured. However, only 5 of them (45%) stayed recovered after a period of two months that elapsed from the completion of therapy. Of the 8 dogs with recurrent pyoderma treated by antibiotics only, 6 (75%) recovered quickly but only 3 of them (38%) stayed healthy after 2 months elapsing from the therapy termination. Of the 10 dogs treated by antibiotics combined with immunomodulators, 8 (80%) regained health within a therapeutic period and 7 of them (70%) remained completely cured after 2 months from completion of therapy. The durations of treatment in dogs with the fi rst occurrence of pyoderma and those with recurrent pyoderma were 8.4 and 10.5 weeks, respectively, the difference begin signifi cant. Hair lenght and percentage of the skin area affected had no effect on the therapy duration. The disappearance of pruritus preceded the successful treatment. The results suggest that the joint treatment of deep pyodermas in dogs by antibiotics and immunomodulators may be superior to the purely antibiotic therapy, because of a stronger suppressive effect on the disease relapse.
Pyoderma represents a large group of canine skin diseases that are diffi cult to treat. These are mostly infl ammations of secondary nature linked to coagulase-positive Staphylococcus spp. Purulent skin infl ammation is not a defi nitive diagnosis, but only a clinical symptom, which masks the main (primary or secondary) cause of the disease; sometimes several factors can play a role in triggering the disease. A major problem consists in increased pruritus which prevents the skin from healing. Self-mutilation due to the pruritus causes other infective skin changes (Rybníček 1999; Chabanne et al. 2000; De Boer and Marsella 2001; Craig 2003) .
Suitable antibiotics may be selected based on experience and observation, especially in case of surface pyoderma after cytological examination of pus and positive bacterial cultivation from an intact pustule. Bacteriological testing and sensitivity to antibiotics must be carried out in case of deep pyoderma, recurrent pyoderma, or if the antibiotic therapy proves to be unsuccessful. Tests may be repeated during the therapy (Scott et al. 2001) . Antibiotics with bacteriostatic effect are suitable for superfi cial pyoderma. Antibiotics with bactericide effect are the drug of choice for cases of recurrent deep pyoderma and for weakened individuals (Lloyd and Grant 1996) . Recommended doses for individual antibiotic groups according to individual authors are shown in Table 1 .
Cephalexin dosed at 15 -30 mg·kg -1 p.o. q 12 -24 h has a quick effect, and it also kills staphylococci located on mucosal membranes (Lloyd and Grant 1996) . Dosing according to Mason and Kietzmann (1999) 
Materials and Methods
Twenty nine dogs of various breeds were included in the therapy of deep pyoderma study group (Labrador Retriever, English Bulldog, Golden Retriever, Shar-pei, Bernese Mountain Dog, etc.), the average age of dogs was 6 years (from 2 to 10 years) and sex representation was 13 females and 16 males. Dogs with deep pyoderma (n = 29) formed a group (n = 18) with idiopathic recurrent deep pyoderma (they were previously treated with antibiotics, antibiotics combined with glucocorticoids, and glucocorticoids); while another group consisted of dogs (n = 11) with the fi rst episode of deep pyoderma, that were never treated before. According to the therapy method, 29 dogs with deep pyoderma were divided into three groups. The fi rst group of dogs with recurrent deep pyoderma (n = 10) received cephalexin (Ceporex ® ) dosed at 30 mg·kg -1 p.o. q 24 h combined with Baypamune ® i. m. pro toto, 1 × per week. The second group of dogs with recurrent deep pyoderma (n = 8) received cephalexin (Ceporex ® ) dosed at 30 mg·kg -1 p.o. q 24 h and the third group of dogs (n = 11) with the fi rst episode of deep pyoderma without previous treatment were also given cephalexin (Ceporex ® ) dosed at 30 mg·kg -1 p.o. q 24 h. The treatment length ranged between 9 -11 weeks. Their health status was continuously monitored. The group of dogs with i. m. administration of Baypamune ® was checked once per week, while other groups once per two weeks. In our study of 29 tested dogs with deep pyoderma, we bacteriologically examined (n = 10) randomly selected dogs.
Statistical analysis
Dogs with deep pyoderma were tested with t-test, amended with the test of equality of variances of compared selections. If the selection variances were not equal, the Welch's analysis of variance was used as a signifi cance test. Percentage differences were tested with Wilcoxon's non-parametric test. If the variances were unequal (heteroskedasticity), we again used the Welch's modifi cation of variance analysis. The relation between two quantitative variables was analyzed using the linear regression method. We used the JMP program (SAS Institute Inc. 2005) for all statistical examinations.
Results
From the total number of 29 dogs with deep pyoderma, 22 animals were cured at the end of therapy (76%), and after two months the success rate of the therapy decreased due to recurrence, to 15 patients (52%). In individual groups of dogs divided according to therapy, the situation was as follows: after two months from the end of therapy, there were relapses in three cases in the group of dogs (n = 11) with the fi rst episode of the disease and treated with antibiotics Cephalexin (Ceporex ® 30 mg·kg -1 p.o. q 24 h for 9 -11 weeks), so the relative number of cured dogs decreased from 73% to 45% (Fig. 1) .
In the group of dogs (n = 8) with relapses, treated also with antibiotics cephalexin (Ceporex ® 30 mg·kg -1 p.o., 1 × per day for 9 -11 weeks) there were three recurrent cases, the relative number of cured dogs decreased from 75% to 38%. One relapse was recorded in 
o. q 24 h).
After the end of therapy, we had an 80% (i.e. 8 cured of 10 dogs) success rate in dogs (n = 10) treated with antibiotic in combination with immunomodulators, in contrast to the group of dogs treated with antibiotics only (n = 19), where the success rate of the therapy was 70% (i.e. 14 cured of 19 dogs). After two months, the success rate of the therapy in the group of dogs treated with antibiotics and immunomodulators decreased due to relapse to 70% (i.e. 7 of 10 dogs), and in dogs treated with antibiotics only there was a signifi cant decrease in the therapy success rate due to relapse to 41% (i.e. 8 cured of 19 dogs).
The average length of therapy with antibiotics and antibiotics in combination with immunomodulators was 9.6 weeks. Differences in the length of therapy between sexes were not found (t-test males 9.8 weeks, females 9.4 weeks, P = 0.51). Hair length and the percentage of affected skin surface had no effect on the length of treatment (P = 0.79), and neither did animal weight (P = 0.19). Dogs with recurrent deep pyoderma (n = 18) healed 14 days longer than the patients with the fi rst episode of the disease (n = 11), treated only with cephalexin. In dogs with relapse, the treatment period was 10.5 weeks and in dogs with the fi rst episode of the disease it was 8.4 weeks (P < 0.001). The period of pruritus resolution had a signifi cant predictive effect on the total length of treatment (Fig. 2) . Earlier disappearance of pruritus indicated shorter treatment (P = 0.004). No signifi cant relation between age and length of treatment was established (P = 0.64).
In our study of 29 tested dogs with deep pyoderma, we randomly chose 10 dogs for bacteriological examination. In (n = 7) dogs we diagnosed Staphylococcus intermedius (70%), one E. coli, Streptococcus spp. and Actinomyces spp.
Discussion
Available studies on pharmacokinetics of cephalexin after oral administration (Rilexin Table 2 . Overview of absolute and relative numbers of treated and cured dogs with deep pyoderma after the end of treatment and relapses after 2 months plasma was achieved in 1.5 h after administration (Ehinger and Kietzmann 2002) . No visible difference in the pharmacokinetics of both preparations was determined (Ehinger and Kietzmann 2002). In our study, we used cephalexin in Ceporex ® 30 mg·kg -1 p.o. q 24 h for 9 -11 weeks (Guaguere et al. 1998 ). This dosage, compared to 15 mg·kg -1 p.o. q 12 h, reportedly has a similar therapeutic effect and administration of the preparation × 1 per day is more convenient for the animal owners. Baypamune ® activates NK (natural killer) cells, stimulates lymphocytic proliferation, and activates macrophages and production of interleukins and antiviral interferon. Baypamune ® is suitable for modulation of non-specifi c immunity reaction and to stimulate suppressed immunity after the end of administration of immunosuppressive doses of steroids (Winnicka et al. 2000) .
In the clinical study dealing with dogs with deep pyoderma, Baypamune ® was administered simultaneously with antibiotics cephalexin (Ceporex ® ) in all cases of recurrent deep pyoderma that were previously treated with antibiotics and steroids. After the end of therapy, no signifi cant difference was observed in the success rate of treatment between the group treated with antibiotics and immunomodulators -80% (i.e. 8 of 10 dogs), and the group treated with antibiotics only -70% (i.e. 14 of 19 dogs). In dogs with deep pyoderma whose clinical status during treatment did not improve, the primary cause might have been an autoimmune disease. After two months, the success rate of therapy in the group of dogs treated with antibiotics and immunomodulators decreased due to relapse to 70% (i.e. 7 of 10 dogs) and in dogs treated only with antibiotics to 41% (i.e. 8 of 19 dogs). Signifi cant decreasing of the number of recurrent cases indicates a positive effect of immunomodulators on the long-term stabilization of immunity status, which may be partly responsible for the resulting clinical condition. Shorter treatment in dogs treated with antibiotics combined with immunomodulators, as quoted by Winiarzcyk et al. (1998) in his studies, was not observed. The success rate of the therapy in dogs with relapse treated with antibiotics and antibiotics in combination with immunomodulators increased by over 50% compared to the previous treatment with antibiotics and glucocorticoids, and in dogs with relapse that were treated with antibiotics and immunomodulators it was successful in over 70%. This result indicates a good choice of antibiotics (dosage and period of administration) and the effect of immunomodulator on clinical improvement.
Dogs with recurrent deep pyoderma were treated 14 days longer than patients with the fi rst episode of deep pyoderma. There was a signifi cant decrease in the number of relapses in affected dogs that received Baypamune ® combined with cephalexin (Ceporex ® Terapie hlubokých pyodermií psů cefalexiny a imunomodulátory Z 29 psů bylo s prvním výskytem hluboké pyodermie léčeno (n = 11) antibiotiky cefalexiny (Ceporex ® 30 mg·kg -1 p.o., 1× denně 9 -11 týdnů) s úspěšností 73 %. Po dvou měsících po ukončení léčby došlo k recidivě a relativní počet vyléčených se snížil na 45 %. 18 psů s recidivující pyodermií, z toho (n = 8) bylo léčeno antibiotiky, relativní počet vyléčených psů se snížil z 75 % na 38 % a (n = 10) bylo léčeno antibiotiky v kombinaci s imunomodulátory (Ceporex ® v kombinaci s Baypamune ® aplikovaný 1× týdně i.m. (9 -11 týdnů), relativní počet vyléčených psů se snížil z 80 % na 70 %. U psů s recidivou (n = 18) byla délka léčby 10,5 týdne a u psů (n = 11) s prvním výskytem onemocnění 8.4 týdne (P < 0.001). Nebyly zjištěny rozdíly v délce léčby mezi samci (9.8 týdne) a samicemi (9.4 týdne), (P = 0.51). Délka srsti a procento postižené plochy kůže (P = 0.79) stejně jako hmotnost zvířete (P = 0.19) a věk (P = 0.64) neměl vliv na délku léčby. Psi s rekurentní hlubokou pyodermií se uzdravovali o 14 dní později než pacienti s prvním výskytem onemocnění (n = 11). Dřívější vymizení pruritu indikovalo kratší dobu léčby (P = 0.004). Výrazná byla úspěšnost v terapii imunomodulátory (Baypamune ® ) v kombinaci s antibiotiky (Ceporex ® ) a to především v signifi kantním snížení relativního počtu recidiv u skupiny psů s rekurentní hlubokou pyodermií
